- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about CMPS
Recent news which mentions CMPS
The Promise Of Psilocybin When It Comes To Mental Health, And How COMPASS Pathways (NASDAQ: CMPS) Is Advancing It
October 11, 2023
Tickers
CMPS
From Benzinga
Psyched: Steve Cohen's New Biopharma Bet, California Gov. Authorizes Medical Psychedelics & More
October 06, 2023
From Benzinga
COMPASS Pathways Is Accelerating Patient Access To Evidence-Based Innovation In Mental Health Care
October 05, 2023
From Benzinga
Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More
October 02, 2023
From Benzinga
Don’t Miss the Boom: 3 Psychedelic Stocks Set to Explode Higher
September 27, 2023
From InvestorPlace
Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More
September 26, 2023
From Benzinga
Psyched: MDMA Trials For PTSD, Congressional Amendments, Scotland's Consumption Site & More
September 18, 2023
From Benzinga
One Year Into Kabir Nath's Leadership, Compass Pathways' (NASDAQ: CMPS) Phase 3 Trial For Innovative Treatment Resistant Depression Progressing
September 18, 2023
From Benzinga
Swedish Foundation Supports Mental Health Innovation With New €3M Psychedelic Science Initiative
September 13, 2023
Tickers
CMPS
From Benzinga
NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years
September 12, 2023
From Benzinga
What's Spurring The Growth Of The Psychedelics Market – And How One Company Is Helping As Part Of The Vanguard In This Emerging Field
September 12, 2023
Tickers
CMPS
From Benzinga
Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More
September 11, 2023
From Benzinga
Compass Pathways Explores AI-Powered Predictive Model On Psilocybin Therapy For Depression
September 06, 2023
Tickers
CMPS
From Benzinga
Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More
September 05, 2023
From Benzinga
Psyched: Psilocybin For Gambling Addiction, Ex-NHL Player's Retreat, Fellini's LSD Creativity, Surveys, Financing & More
August 28, 2023
From Benzinga
From Motley Fool
Psyched: Fed Study On Psychedelics, Janet Yellen's Magic Mushrooms, Financing Deals & Quarterly Reports
August 21, 2023
From Benzinga
COMPASS' Securities Purchase Agreement Is Big News
August 18, 2023
From Benzinga
Up To $285M In Financing: COMPASS Pathways' Private Placement Backed By 'Select Group' Of Investors
August 16, 2023
Tickers
CMPS
From Benzinga
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
August 14, 2023
From Benzinga
Atai's Q2 2023 Plus Clinical Data On Ibogaine-Opioid Study, Pipeline's Psilocybin, DMT, Ketamine & MDMA
August 10, 2023
From Benzinga
Compass Pathways Plc (CMPS) Q2 2023 Earnings Call Transcript
August 04, 2023
Tickers
CMPS
From Motley Fool
COMPASS Pathways Q2 2023: $148.2M Cash Position, Steady Quarter And 'Strong Progress Across The Business'
August 03, 2023
From Benzinga
Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More
August 03, 2023
From Benzinga
From Benzinga
Tickers
CMPS
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.